Ruxolitinib before, during, and after transplant for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old (or older than 75 but very healthy and active).
- You have been diagnosed with myelofibrosis or an MDS/MPN overlap syndrome.
- You are willing to take ruxolitinib (a JAK inhibitor) for at least 8 weeks before transplant and continue for 12 months after.
- You have a suitable stem cell donor (a matched sibling or matched unrelated donor).
- Your heart, lungs, kidneys, and liver are working well enough for transplant.
- You have not had a prior stem cell transplant and do not have active infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study follows patients with myelofibrosis (a type of bone marrow cancer) who are already taking or have taken ruxolitinib. Researchers will review medical records to understand how well the medicine works in everyday practice.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Hear when a new Myelodysplastic/Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.